Currently Enrolling
Disease Indication | Study Information |
---|---|
Immune-Checkpoint Inhibitor-Induced Arthritis |
Synovial Tissue and Peripheral Blood Phenotypes in Immune Checkpoint Inhibitor–Induced Arthritis
|
Still’s Disease with Macrophage Activation Syndrome |
NI-0501-14: A Two-Cohort, Open-Label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics, of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease or With MAS in Systemic Lupus Erythematous
|
Active Inflammatory Arthritis |
Development and Validation of Applying Thermal Imaging as An Adjunct Tool to Augment Physician’s Assessment in The Telehealth Setting
|
System Lupus Erythematosus |
SL0043: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus
|
Cutaneous Dermatomyositis |
CUDM001: An Open-Label Pilot Study to Evaluate the Efficacy and Safety of Baricitinib in Subjects with Cutaneous Dermatomyositis
|
Open to All |
Rheumatic Disease Biorepository & Patient Registry
|
Upcoming Study Areas
Stay tuned for more information on upcoming studies for Systemic Lupus Erythematosus, Rheumatoid Arthritis, Giant Cell Arteritis, Lupus Nephritis, Psoriatic Arthritis and Scleroderma.
Contact Us
Connect with the team via email or call to speak with our Research Manager.
Email: RheumResearch@medicine.washington.edu
Phone: 206-616-5330
If you have questions, are interested in participating, or want to sponsor a study at our site, let us know!